Clinical trials: Oncology Patients
Relapsed and Refractory Multiple Myeloma (RRMM)
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after…
- Trial name
- NCT05673967
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Primary Objective: To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m^2 (Arm A) or 20 mg/m^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS) in participants with metastatic…
- Trial name
- FIRSTANA (NCT01308567)
- Testing
- Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone
- Where
- 167 sites in United States, Australia and 23 more
- Volunteers
- 1,168 people
- Sponsor
- Sanofi
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Neoplasms, Hematologic
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with…
- Trial name
- NCT01594723
- Testing
- 120 mg LY2784544
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Chronic Myelogenous Leukemia - Chronic Phase
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior…
- Trial name
- AIM4CML (NCT04666259)
- Testing
- ABL001
- Where
- 26 sites in United States
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor and Lymphoma
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the…
- Trial name
- NCT07333469
- Testing
- HX111 for injection
- Volunteers
- 70 people
- Sponsor
- Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Advanced Malignant Tumors
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
This is a Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.
- Trial name
- NCT06223841
- Testing
- IAP0971
- Where
- China
- Volunteers
- 50 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Resectable Non-small Cell Lung Cancer
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called…
- Trial name
- NCT06161441
- Testing
- Fianlimab, Cemiplimab, Pemetrexed
- Where
- 123 sites in United States, Australia and 10 more
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Myelofibrosis
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to…
- Trial name
- NCT04576156
- Testing
- Imetelstat, Best Available Therapy (BAT)
- Where
- 144 sites in United States, Argentina and 24 more
- Volunteers
- 327 people
- Sponsor
- Geron Corporation
Advanced Solid Tumor, HR+/HER2- Breast Cancer
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4（CDK4）and CDK6 kinase activity. This Phase I study is a first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, and…
- Trial name
- NCT04282031
- Testing
- BPI-1178, Fulvestrant, Letrozole
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Beta Pharma (Suzhou) Co., Ltd.
Melanoma
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
The purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic product GSK 2132231A in preventing disease relapse when given to melanoma patients, after surgical removal of their tumor.
- Trial name
- NCT00796445
- Testing
- GSK 2132231A
- Where
- 257 sites in United States, Argentina and 30 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Colitis, Ulcerative, Crohn Disease
Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
The purpose of this study is to establish the incidence of sub-optimal response to anti-TNF therapy in UC and CD participants.
- Conditions
- Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
- Trial name
- NCT03090139
- Testing
- Anti-TNF Therapy
- Where
- 76 sites in Argentina, China and 8 more
- Volunteers
- 1,731 people
- Sponsor
- Takeda
Meningioma
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real time detection and visualization of meningiomas during tumor resection…
- Trial name
- MEN-301 (NCT04305470)
- Testing
- Gleolan
- Where
- 17 sites in United States, Austria and 1 more
- Volunteers
- 108 people
- Sponsor
- NX Development Corp
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Breast Cancer Metastatic
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination…
- Trial name
- NCT05155566
- Where
- 2 sites in Argentina, United Kingdom
- Volunteers
- 847 people
- Sponsor
- Pfizer
Hematologic Malignancies
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
This study is a first-in-human (FIH) study which is required to understand the safety, tolerability, pharmacokinetics and preliminary efficacy of RJK-RT2831 injection in patients with hematologic malignancies
- Trial name
- NCT06756451
- Testing
- RJK-RT2831 dose-escalation phase Ia, RJK-RT2831 Dose Expansion Phase Ib
- Where
- 16 sites in China
- Volunteers
- 71 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Magnetic Resonance Imaging
Gadobutrol Magnevist-controlled Body Study
The purpose of the study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the body/extremities regions.
- Trial name
- NCT01050829
- Testing
- Gadobutrol (Gadovist, BAY86-4875), Gadopentetate Dimeglumine (Magnevist, BAY86-4882)
- Where
- 15 sites in China, Japan and 1 more
- Volunteers
- 370 people
- Sponsor
- Bayer
Squamous Cell Carcinoma of the Head and Neck
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT05459129
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.
- Trial name
- NCT05830045
- Testing
- QLP2117
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Prostate Cancer
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.
The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.
- Trial name
- One registry (NCT07645872)
- Where
- 5 sites in France
- Volunteers
- 3,000 people
- Sponsor
- EDAP TMS S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.